NCT04967196View on ClinicalTrials.gov

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 16, 2021

Primary Completion Date

April 17, 2024

Study Completion Date

April 17, 2024

Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaUnresectable Melanoma
Interventions
BIOLOGICAL

Ipilimumab

Given via DoseConnect device or IV

BIOLOGICAL

Nivolumab

Given IV

PROCEDURE

Lymph Node Assessment

Undergo lymphatic imaging with ICG

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04967196 - Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma | Biotech Hunter | Biotech Hunter